The Two Giants of GLP-1 Therapy
Semaglutide and Tirzepatide represent the current gold standard in GLP-1 medications for weight loss. While both target the GLP-1 receptor, they have fundamental differences that affect their efficacy and side effect profiles.
Mechanism Comparison
Semaglutide (Single Agonist)
Semaglutide activates only the GLP-1 receptor. It's a modified version of human GLP-1 with 94% structural similarity. Brand names include Ozempic (for diabetes) and Wegovy (for weight loss).
Tirzepatide (Dual Agonist)
Tirzepatide is a "twincretin"—it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action provides:
- Enhanced insulin secretion
- Greater appetite suppression
- Improved fat metabolism
- Potentially better tolerability
Clinical Trial Results Head-to-Head
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Average Weight Loss | 15-17% | 20-22.5% |
| Participants Losing >20% | ~32% | ~57% |
| HbA1c Reduction | ~1.5% | ~2.1% |
| Trial Duration | 68 weeks | 72 weeks |
Dosing Schedules
Semaglutide Titration
- Week 1-4: 0.25mg weekly
- Week 5-8: 0.5mg weekly
- Week 9-12: 1.0mg weekly
- Week 13-16: 1.7mg weekly
- Week 17+: 2.4mg weekly (maintenance)
Tirzepatide Titration
- Week 1-4: 2.5mg weekly
- Week 5-8: 5mg weekly
- Week 9-12: 7.5mg weekly
- Week 13-16: 10mg weekly
- Week 17-20: 12.5mg weekly
- Week 21+: 15mg weekly (maintenance)
Side Effect Comparison
Both medications share similar GI-related side effects, but their frequency and severity differ:
Common Side Effects (Both)
- Nausea (especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- Fatigue
Key Differences
Tirzepatide users often report milder GI symptoms, possibly because the GIP component has a protective effect on the stomach. Many find the titration phase more tolerable.
Semaglutide has more long-term safety data, having been on the market longer. Some users report more pronounced appetite suppression.
Cost Considerations
Brand-name versions of both are expensive ($900-1,300/month without insurance). Compounded versions offer significant cost savings while providing the same active ingredients.
Who Should Choose Which?
Consider Tirzepatide If:
- You want maximum weight loss potential
- You have significant insulin resistance or prediabetes
- You've tried Semaglutide and plateaued
- You're sensitive to GI side effects
Consider Semaglutide If:
- You prefer a medication with longer market history
- You're starting GLP-1 therapy for the first time
- Cost is a primary concern (more generic options)
- You have specific cardiac risk factors (more cardiovascular outcome data)
The Bottom Line
Both medications are highly effective. Tirzepatide shows superior weight loss in clinical trials, but Semaglutide has more long-term safety data. The best choice depends on your individual health profile, goals, and response to treatment.